.jpg)
NANOCONJUGATES FORMED FROM DENDRITIC MOLECULES AND PEPTIDES AS ANTITUMOUR AGENTS AGAINST CANCER
WO18142007
The present invention relates to the formation of nanoconjugates exhibiting antitumour activity, mainly against advanced prostate cancer, but without excluding others. The nanoconjugates are formed from dendritic systems (dendrimers or dendrons) and neuropeptides. The dendritic molecules mainly have a carbosilane structure with ammonium groups on the periphery. The peptides are preferably from the glucagon/secretin family (e.g.VIP, GHRH, PACAP). The combination of these two systems leads to a nanoconjugate with anticarcinogenic properties that differ from those of their individual precursors. The antitumour activity is reflected in the growth inhibition and death of tumour cells in advanced prostate cancer (PC3) and, in addition, said nanoconjugates favour cell adhesion and prevent tumour cell migration processes, in other words metastasis processes.
The properties of nanoconjugates allow treating tumor cells of advance prostate cancer. Dendritic systems can be used as transporters of drugs or antitumor nucleic acids due to their ability to be absorbed "in vivo" in tumor zones and to internalize the treatment in cancer cells. The dendrimer also remains in the tumor zone without returning to the bloodstream. The necessary development, for the commercial exploitation of this patent, does not entail a high technical difficulty.